🇺🇸 FDA
Pipeline program

Liposomal bupivacaine

Droege 2016

Phase 2 small_molecule completed

Quick answer

Liposomal bupivacaine for Blunt Chest Wall Trauma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Blunt Chest Wall Trauma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials